1. Home
  2. TARS vs MC Comparison

TARS vs MC Comparison

Compare TARS & MC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tarsus Pharmaceuticals Inc.

TARS

Tarsus Pharmaceuticals Inc.

HOLD

Current Price

$68.26

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Logo Moelis & Company

MC

Moelis & Company

HOLD

Current Price

$54.63

Market Cap

4.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TARS
MC
Founded
2016
2007
Country
United States
United States
Employees
N/A
1416
Industry
Medicinal Chemicals and Botanical Products
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
4.1B
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
TARS
MC
Price
$68.26
$54.63
Analyst Decision
Strong Buy
Hold
Analyst Count
10
11
Target Price
★ $99.80
$67.50
AVG Volume (30 Days)
652.8K
★ 967.6K
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
★ 4.72%
EPS Growth
★ 48.21
N/A
EPS
N/A
★ 0.75
Revenue
★ $451,360,000.00
N/A
Revenue This Year
$61.17
$14.07
Revenue Next Year
$26.47
$17.57
P/E Ratio
★ N/A
$73.35
Revenue Growth
★ 146.71
N/A
52 Week Low
$53.89
$51.06
52 Week High
$91.53
$78.22

Technical Indicators

Market Signals
Indicator
TARS
MC
Relative Strength Index (RSI) 39.23 39.55
Support Level $60.95 $51.06
Resistance Level $74.51 $57.54
Average True Range (ATR) 3.34 2.00
MACD -0.37 0.17
Stochastic Oscillator 2.22 46.12

Price Performance

Historical Comparison
TARS
MC

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

About MC Moelis & Company

Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. It generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States, followed by Europe and the rest of the World.

Share on Social Networks: